stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
34.72
2.19
+6.73%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) P/E ratio
Pharvaris N.V. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | n/m |
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| PHVS Pharvaris N.V. | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| RXRX Recursion Pharmaceuticals, Inc. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| ADMA ADMA Biologics Inc compare | 16.7× |
| VCEL Vericel Corporation compare | 77.8× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)